Dupilumab (Dupixent) is approved to treat adults and children 6 months old and older with moderate to severe atopic dermatitis that hasn't responded well to topical medications. Dupilumab works ...

Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults and adolescents 6 months and older with ...

The drug will enter the UK market as an alternative to Sanofi and Regeneron’s widely-used IL-4 and IL-13 inhibitor Dupixent (dupilumab), which was backed for atopic dermatitis in 2018 and ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the ... sales of Dupixent. Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma ...

Over the next 10 years, GlobalData has predicted that Dupixent will remain the most prescribed biologic therapy for atopic dermatitis, with global sales of $5.3 billion in 2027.

LEO will also able to offer patients an alternative to the blockbuster Sanofi/Regeneron Pharmaceuticals drug Dupixent. Atopic dermatitis patients now have a new therapeutic option that comes as a ...

‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...

including atopic dermatitis (AD), in which it is considered the gold standard, says GlobalData, a data and analytics company. “Having Dupixent as the gold standard for AD, Sanofi has set a high ...